Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CDCatherine DiefenbachNSNirav N. ShahITIris To

Discussion

Loading...

Member takes

Overview

Randomized trial showed improved progression-free survival in patients with relapsed B-cell lymphoma, indicating favorable clinical efficacy of mosunetuzumab with polatuzumab vedotin.

Key Points

  • To evaluate the long-term follow-up and efficacy of mosunetuzumab combined with polatuzumab vedotin compared to rituximab plus polatuzumab vedotin in relapsed B-cell lymphoma.
  • Patients with relapsed B-cell lymphoma were randomized to receive mosunetuzumab plus polatuzumab vedotin or rituximab plus polatuzumab vedotin.
  • The primary endpoint was objective response rate assessed by an independent review committee based on Lugano 2014 criteria.
  • Cytokine release syndrome was monitored according to ASTCT standards.
  • The best overall response rate was 78% for mosunetuzumab plus polatuzumab vedotin versus 50% for rituximab plus polatuzumab vedotin.
  • Median progression-free survival was significantly longer at 25.4 months for the mosunetuzumab arm compared to 6.4 months for rituximab.
  • No new safety signals were identified, with adverse events being manageable.

Cite This Study

Diefenbach et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d44chttps://doi.org/10.1182/blood-2025-1020
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study2025 · 1 citations
  2. 2A Randomized Phase <scp>II</scp> Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma2026 · 1 citations
  3. 3Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups.2026
  4. 4Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial2026
  5. 5Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).2024 · 2 citations